Limits...
miR-630 overexpression in hepatocellular carcinoma tissues is positively correlated with alpha-fetoprotein.

Zhang JW, Li Y, Zeng XC, Zhang T, Fu BS, Yi HM, Zhang Q, Jiang N - Med. Sci. Monit. (2015)

Bottom Line: The present study found that miR-630 expression was significantly increased in HCC tissues and cells compared with their normal counterparts. miR-630 expression level did not significantly chang at stage I but was markedly increased at advanced TNM stage (stage II~III).In addition, the increased expression of miR-630 in tissues of HCC appeared in patients who exhibited elevated serum levels of AFP (>25 ng/ml), but not in those with normal AFP levels (≤25 ng/ml).These results suggest that miR-630 is associated with tumor progression of hepatocellular carcinoma and may be a potential prognosis indicator.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatic Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (mainland).

ABSTRACT

Background: MicroRNA-630 (miR-630) has been shown to be involved in various human malignancies. However, its role in hepatocellular carcinoma (HCC) remains unknown.

Material and methods: TaqMan qRT-PCR assay was performed to detect the expression of miR-630 in 42 pairs of HCC tissues and corresponding noncancerous hepatocellular tissues, and its correlations with clinicopathologic features and serum alpha-fetoprotein (AFP) level of patients were analyzed.

Results: The present study found that miR-630 expression was significantly increased in HCC tissues and cells compared with their normal counterparts. miR-630 expression level did not significantly chang at stage I but was markedly increased at advanced TNM stage (stage II~III). In addition, the increased expression of miR-630 in tissues of HCC appeared in patients who exhibited elevated serum levels of AFP (>25 ng/ml), but not in those with normal AFP levels (≤25 ng/ml). The miR-630 expression in carcinoma tissues revealed a positive correlation with the levels of serum alpha-fetoprotein (AFP; R2=0.768).

Conclusions: These results suggest that miR-630 is associated with tumor progression of hepatocellular carcinoma and may be a potential prognosis indicator.

Show MeSH

Related in: MedlinePlus

Correlation between miR-630 expression and serum AFP levels. (A) The expression of miR-630 in hepatocellular carcinoma tissues in patients with normal serum AFP (≤25 ng/ml; n=13) and abnormal serum AFP (>25 ng/ml; n=11) is shown. (B) The correlation analysis of miR-630 expression in hepatocellular carcinoma tissues and serum AFP levels is shown.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4356187&req=5

f3-medscimonit-21-667: Correlation between miR-630 expression and serum AFP levels. (A) The expression of miR-630 in hepatocellular carcinoma tissues in patients with normal serum AFP (≤25 ng/ml; n=13) and abnormal serum AFP (>25 ng/ml; n=11) is shown. (B) The correlation analysis of miR-630 expression in hepatocellular carcinoma tissues and serum AFP levels is shown.

Mentions: We further determined the relationship between miR-630 expression and serum AFP level after re-measuring serum AFP levels of all patients using ELISA. The result showed that, consistent with clinical reviewed data (patient serum AFP level was determined using radioimmunoassay method), among all 42 patients, 11 patients exhibited normal serum AFP levels (≤25 ng/ml), while the other 31 patients exhibited abnormal serum AFP levels (>25 ng/ml). In adjacent noncancerous tissues, there was no difference of the expression of miR-630 between patients with normal and abnormal serum AFP levels (Figure 3A). However, in carcinoma tissues, while in patients with normal AFP levels the miR-630 expression was not significantly different from the adjacent noncancerous tissues (p>0.05; Figure 3A); a significant increase of miR-630 appeared in those with abnormal AFP levels (1.76-fold vs. the adjacent noncancerous tissues; p=0.003; Figure 3A). Correlation analysis result showed that miR-630 levels in carcinoma tissues were positively correlated with serum AFP value (R2=0.768, p<0.001; Figure 3B).


miR-630 overexpression in hepatocellular carcinoma tissues is positively correlated with alpha-fetoprotein.

Zhang JW, Li Y, Zeng XC, Zhang T, Fu BS, Yi HM, Zhang Q, Jiang N - Med. Sci. Monit. (2015)

Correlation between miR-630 expression and serum AFP levels. (A) The expression of miR-630 in hepatocellular carcinoma tissues in patients with normal serum AFP (≤25 ng/ml; n=13) and abnormal serum AFP (>25 ng/ml; n=11) is shown. (B) The correlation analysis of miR-630 expression in hepatocellular carcinoma tissues and serum AFP levels is shown.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4356187&req=5

f3-medscimonit-21-667: Correlation between miR-630 expression and serum AFP levels. (A) The expression of miR-630 in hepatocellular carcinoma tissues in patients with normal serum AFP (≤25 ng/ml; n=13) and abnormal serum AFP (>25 ng/ml; n=11) is shown. (B) The correlation analysis of miR-630 expression in hepatocellular carcinoma tissues and serum AFP levels is shown.
Mentions: We further determined the relationship between miR-630 expression and serum AFP level after re-measuring serum AFP levels of all patients using ELISA. The result showed that, consistent with clinical reviewed data (patient serum AFP level was determined using radioimmunoassay method), among all 42 patients, 11 patients exhibited normal serum AFP levels (≤25 ng/ml), while the other 31 patients exhibited abnormal serum AFP levels (>25 ng/ml). In adjacent noncancerous tissues, there was no difference of the expression of miR-630 between patients with normal and abnormal serum AFP levels (Figure 3A). However, in carcinoma tissues, while in patients with normal AFP levels the miR-630 expression was not significantly different from the adjacent noncancerous tissues (p>0.05; Figure 3A); a significant increase of miR-630 appeared in those with abnormal AFP levels (1.76-fold vs. the adjacent noncancerous tissues; p=0.003; Figure 3A). Correlation analysis result showed that miR-630 levels in carcinoma tissues were positively correlated with serum AFP value (R2=0.768, p<0.001; Figure 3B).

Bottom Line: The present study found that miR-630 expression was significantly increased in HCC tissues and cells compared with their normal counterparts. miR-630 expression level did not significantly chang at stage I but was markedly increased at advanced TNM stage (stage II~III).In addition, the increased expression of miR-630 in tissues of HCC appeared in patients who exhibited elevated serum levels of AFP (>25 ng/ml), but not in those with normal AFP levels (≤25 ng/ml).These results suggest that miR-630 is associated with tumor progression of hepatocellular carcinoma and may be a potential prognosis indicator.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatic Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (mainland).

ABSTRACT

Background: MicroRNA-630 (miR-630) has been shown to be involved in various human malignancies. However, its role in hepatocellular carcinoma (HCC) remains unknown.

Material and methods: TaqMan qRT-PCR assay was performed to detect the expression of miR-630 in 42 pairs of HCC tissues and corresponding noncancerous hepatocellular tissues, and its correlations with clinicopathologic features and serum alpha-fetoprotein (AFP) level of patients were analyzed.

Results: The present study found that miR-630 expression was significantly increased in HCC tissues and cells compared with their normal counterparts. miR-630 expression level did not significantly chang at stage I but was markedly increased at advanced TNM stage (stage II~III). In addition, the increased expression of miR-630 in tissues of HCC appeared in patients who exhibited elevated serum levels of AFP (>25 ng/ml), but not in those with normal AFP levels (≤25 ng/ml). The miR-630 expression in carcinoma tissues revealed a positive correlation with the levels of serum alpha-fetoprotein (AFP; R2=0.768).

Conclusions: These results suggest that miR-630 is associated with tumor progression of hepatocellular carcinoma and may be a potential prognosis indicator.

Show MeSH
Related in: MedlinePlus